Laura Hansen

Title: Laura Hansen: Innovator in Cancer Treatment

Introduction

Laura Hansen is a prominent inventor based in Bellevue, NE (US), known for her significant contributions to cancer treatment through innovative peptide technologies. With a total of three patents to her name, she has made strides in developing systems and methods that target cancerous cells effectively.

Latest Patents

Hansen's latest patents focus on 14-3-3 targeting peptides for cancer treatment. These patents describe systems and methods for treating squamous cell carcinoma and other cancers using targeting peptides. The peptides are designed to interact with SCC cells or other cancerous cells to block or interfere with 14-3-3ε heterodimerization or CDC25A binding to 14-3-3ε. Notable peptide compositions include a first targeting peptide with the structure Trp-Tyr-Trp-Lys-NH (SEQ ID NO: 1), a second targeting peptide with the structure phospho-Ser178; Ac-Thr-Gln-Arg-Gln-Asn-Ser-(PO)-Ala-Pro-Arg-Met-Leu-Ser-Ser-Asn-NH (SEQ ID NO: 2), and a third targeting peptide with the structure phospho-Thr507 residue; Ac-Arg-Thr-Lys-Ser-Arg-Thr(PO)-Trp-Ala-Gly-Glu-Lys-Ser-Lys-Arg-NH (SEQ ID NO: 3).

Career Highlights

Throughout her career, Laura Hansen has worked with notable institutions such as Creighton University and Nutech Ventures. Her work has been instrumental in advancing the field of cancer research and treatment.

Collaborations

Hansen has collaborated with several professionals in her field, including Sandor Lovas and Nicholas Palermo. These collaborations have further enhanced her research and development efforts.

Conclusion

Laura Hansen's innovative work in cancer treatment through peptide technology showcases her dedication to improving healthcare outcomes. Her contributions are paving the way for new therapeutic approaches in oncology.